Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D. Oar A, et al. Among authors: moore a. BMC Cancer. 2021 Aug 19;21(1):936. doi: 10.1186/s12885-021-08666-y. BMC Cancer. 2021. PMID: 34412605 Free PMC article.
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Siva S, et al. JAMA Oncol. 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. JAMA Oncol. 2021. PMID: 34455431 Free PMC article. Clinical Trial.
[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial.
Koh ES, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, Lau E, Khasraw M, Nowak AK, Bailey DL, Moffat BA, Fitt G, Hicks RJ, Coffey R, Verhaak R, Walsh KM, Barnes EH, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas PA, Roach P, Back M, Leonard R, Scott AM. Koh ES, et al. Among authors: moore a. BMJ Open. 2023 Aug 4;13(8):e071327. doi: 10.1136/bmjopen-2022-071327. BMJ Open. 2023. PMID: 37541751 Free PMC article.
Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial.
Khaw P, Do V, Lim K, Cunninghame J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D'Amico R, Bessette P, Mileshkin L, Creutzberg CL, Moore A. Khaw P, et al. Among authors: moore a. Clin Oncol (R Coll Radiol). 2022 Mar;34(3):198-204. doi: 10.1016/j.clon.2021.11.015. Epub 2021 Dec 11. Clin Oncol (R Coll Radiol). 2022. PMID: 34903431 Clinical Trial.
Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial.
Bucknell NW, Kron T, Herschtal A, Hardcastle N, Irving L, MacManus M, Hanna GG, Moore A, Murnane A, Siva S, Ball D; CHISEL coauthors. Bucknell NW, et al. Among authors: moore a. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):378-386. doi: 10.1016/j.ijrobp.2023.04.009. Epub 2023 Apr 21. Int J Radiat Oncol Biol Phys. 2023. PMID: 37087060 Clinical Trial.
Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02).
Phillips C, Pinkham MB, Moore A, Sia J, Jeffree RL, Khasraw M, Kam A, Bressel M, Haworth A. Phillips C, et al. Among authors: moore a. Breast. 2024 Apr;74:103675. doi: 10.1016/j.breast.2024.103675. Epub 2024 Feb 5. Breast. 2024. PMID: 38340685 Free PMC article. Clinical Trial.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Siva S, et al. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. Lancet Oncol. 2024. PMID: 38423047 Clinical Trial.
[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program.
Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, Chua B, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. Barry N, et al. Among authors: moore a. Phys Imaging Radiat Oncol. 2024 Mar 13;30:100568. doi: 10.1016/j.phro.2024.100568. eCollection 2024 Apr. Phys Imaging Radiat Oncol. 2024. PMID: 38585372 Free PMC article.
Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma.
Gaudreault M, Hardcastle N, Jackson P, McIntosh L, Higgs B, Pryor D, Sidhom M, Dykyj R, Moore A, Kron T, Siva S. Gaudreault M, et al. Among authors: moore a. Int J Radiat Oncol Biol Phys. 2024 Apr 26:S0360-3016(24)00564-9. doi: 10.1016/j.ijrobp.2024.04.066. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38679212
6,631 results